LILLY DRN ED

Doctors Without Borders criticized Eli Lilly for high insulin prices, calling for $1 injection pens. The FDA's rejection of Novo Nordisk's new insulin may impact market dynamics for Eli Lilly.

Eli Lilly's stock closed at $818.86, down 1.63% for the day, but up 38.27% year-to-date. Jim Cramer called the performance 'pathetic' and noted that Amgen's recent stock drop might benefit Eli Lilly.

Eli Lilly is noted in the weight loss drug market, especially against Amgen's monthly drug MariTide, contrasting with Eli Lilly's weekly injections.